必发(中国)手机官方网站

3358288340
CN
CN EN
Milestones
Following the philosophy of "Precise Products, Predictable Effects, Health Protection", Kexing Biopharm is devoted to promoting the R&D of quality biopharmaceutical products with improved clinical value, acting as the safeguard of human's health.
  • 1989
    1989
    Shenzhen Kexing Bioproducts Co., Ltd., was established as an industrial base for interferon production.
  • 1996
    1996
    "Human Interferon α1b for Injection" (SINOGEN) was officially approved for production as Class I biological products.
  • 1997
    1997
    Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.
  • 1998
    1998
    "Human Erythropoietin Injection (CHO Cell)" (EPOSINO) was officially approved for production as Class II biological products.
  • 2000
    2000
    Shenzhen Sinovac was recognized by the Ministry of Science and Technology as the "Industrialization Base of National 863 Plan Achievement"
  • 2001
    2001
    "Human Granulocyte Colony-stimulating Factor Injection"(WHITE-C) was officially approved for production.
  • 2002
    2002
    Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO) was officially approved for production.
  • 2009
    2009
    The EPO agent not containing albumin obtained the certificate of invention patent (patent No. ZL200610146206.0).
  • 2014
    2014
    We integrated the traditional Chinese medicine business focusing on KEHUANG CAPSULE around hepatopathy treatment.
  • 2017
    2017
    Our technology center was ratified as the "Shandong Provincial Enterprise-level Technology Center"
  • 2018
    2018
    Our technology center was ratified as the "Jinan Protein Therapeutics Engineering Laboratory".
  • 2019
    2019
    We launched the slogan "Precise Products, Predictable Effects, Health Protection" and the new logo.
  • 2019
    2019
    The company was restructured into Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm).
  • 2020
    2020
    Our technology center was ratified as the "Shandong Protein Therapeutics Engineering Laboratory".
  • 2020
    2020
    Our technology center was ratified as the "Guangdong Gene Engineering Recombinant Protein Therapeutics Engineering Technology Center".
  • 2020
    2020
    The company successfully landed on the A-share technology innovation board with the stock code of 688136, becoming the leader of high quality biologicals.
  • 2020
    2020
    The company was approved to set up the "Shenzhen postdoctoral innovation practice base".
  • 2021
    2021
    Kexing Biopharm signed a Drug Cooperation Agreement with Haichang Biotech to obtain the commercial license of HC007 (a complex preparation for injection, a generic drug of a broad-spectrum anticancer drug) in all regions except the US.
1989 1996 1997 1998 2000 2001 2002 2009 2014 2017 2018 2019 2019 2020 2020 2020 2020 2021
XML 地图